ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements with these filters
Zota Health Care responded to a proxy advisory firm's negative recommendations on upcoming AGM resolutions, defending proposed director remuneration and related party transactions with its subsidiary.
Zota Health Care Limited announced the cessation of Mrs. Varshabahen Gaurang Mehta as an Independent Director effective September 09, 2026, upon the completion of her tenure.
Zota Health Care Limited appointed Mr. Mahaveer Dhariwal as a Non-Executive Independent Director, effective September 3, 2026. The board approved this leadership appointment.
Zota Health Care has fixed September 21, 2026, as the record date for its upcoming Annual General Meeting and final dividend payment.
Zota Health Care Limited's board approved the Notice of the 26th AGM and set the record date for the final dividend. They also appointed a new Independent Director.
Zota reported 67.6% YoY revenue growth in Q1 FY27, driven by Davaindia network expansion. Management expects EBITDA positivity to resume from Q2 and cash breakeven by Q1 FY28.
Zota Health Care's Q1FY27 presentation highlights its massive Davaindia retail generic pharmacy expansion, now reaching 2,825 stores and driving 83% of company revenue.
Zota Health Care Ltd submitted its statement regarding QIP proceeds utilization. The company confirmed no deviation in fund usage for the quarter ended June 30, 2026.
Zota Health Care reported Q1FY27 consolidated revenue of ₹173.60 Crore, up 67.59% YoY. It also added 264 new stores, expanding its network to 2,825 outlets.
Zota Healthcare Ltd reported revenue from operations of ₹173.6 Cr (+67.6% YoY) and a net loss of ₹43.9 Cr for Q1 FY27.
Zota Health Care Limited will hold a board meeting on August 13, 2026, to consider and approve its quarterly unaudited financial results.
Zota Health Care issued a corrigendum to its Consolidated Cash Flow Statement for the year ended March 31, 2026, to rectify typographical errors.
Zota Health Care converted a Rs. 119.52 Crore unsecured loan into equity of its subsidiary Davaindia Health Mart. This debt-to-equity swap improves the group's consolidated net worth.
Zota Health Care acquired 2,35,512 shares in its subsidiary, Davaindia Health Mart, for Rs. 119.52 Crore. The transaction involved converting outstanding unsecured loans into equity.
Zota Health Care disclosed opening 264 Davaindia stores in Q1FY27, raising total stores to 2,825. The expansion underscores robust growth in its retail footprint.
Zota reported robust FY26 performance with 83.86% revenue growth, achieving EBITDA turnaround and significant Davaindia store expansion to 2,579 outlets.
Zota Health Care (FY26) achieved ₹53,865.75 lakhs revenue, driven by its Davaindia generic pharmacy retail chain which now spans 2,579 stores across 23 states.
Zota Health Care reported ₹538.66 Crore revenue for FY26, achieving 83.86% YoY growth. Strong expansion saw the Davaindia network reach 2,579 stores nationwide.
Zota Health Care capped cumulative promoter director remuneration at ₹12.00 Crore annually until 2030. This voluntary move aims to improve corporate governance and capital allocation.
Zota Health Care invested ₹20.20 Crore in its subsidiary, Davaindia Health Mart, via a rights issue. This capital supports strategic store expansion and working capital needs.
Zota Health Care recommended a 10% final dividend (Re. 1 per share) for FY2025-26. The payout remains subject to shareholder approval at the upcoming AGM.
Zota Health Care confirmed zero deviation in utilizing ₹722.50 Crore raised via preferential issues and QIP. Funds were fully deployed toward stated corporate and expansion objects.
Zota Healthcare Ltd reported revenue from operations of ₹163.2 Cr (+67.7% YoY) and a net loss of ₹14.5 Cr for Q4 FY26.
Zota Health Care reported FY26 consolidated revenue of ₹538.66 Crore and recommended a 10% dividend. The board also approved a ₹20.20 Crore investment in its subsidiary.
Zota Health Care appointed actor Akshay Kumar as brand ambassador for its UGO Generic brand. The partnership aims to expand affordable healthcare access across India.
Zota Health Care Limited confirmed full utilization of its ₹179.07 Crore preferential issue proceeds. CRISIL Ratings' report indicates zero unutilized funds as of March 31, 2026.
Zota Health Care Limited shareholders approved a special resolution via postal ballot to authorize the board to provide loans, guarantees, or securities up to ₹1,000 Crore. The resolution, passed with 97.96% majority, enables the company to exceed limits specified under Section 186 of the Companies Act, 2013 for strategic financial flexibility.
Zota Health Care Limited clarified its proposal to increase borrowing and investment limits from ₹500 Crore to ₹1,000 Crore following a proxy advisory report. The company intends to maintain headroom for strategic acquisitions and working capital support for its subsidiary, Davaindia Health Mart Limited, to manage its extensive store network.
Zota Health Care Limited submitted a clarification to NSE regarding its September 2025 financial results. The company corrected a clerical error in the comparative balance sheet data and provided a machine-readable PDF format. Management confirmed there are no changes to the previously reported financial figures.
Zota Health Care Limited announced the addition of 248 Davaindia stores during Q4FY26, bringing its total operative store count to 2,579 as of March 31, 2026. The expansion was driven primarily by 218 new COCO stores managed by its subsidiary. This robust growth reflects the company's continued retail footprint expansion.